Chiron Corp. finalized a settlement agreement with F. Hoffmann-La Roche Ltd. concerning an HIV patent late last week, then announced Monday an agreement to provide InterMune Inc. with its hepatitis C targets. (BioWorld Today)
For reasons that might be as much socio-economic as medical, female sexual arousal disorder (FSAD) has been overlooked in favor of the lucrative market for erectile dysfunction therapies such as the pioneering phosphodiesterase type-5 inhibitor Viagra from Pfizer Inc.
Less than two months after filing a new drug application for Tarceva to treat non-small-cell lung cancer, Genentech Inc. and OSI Pharmaceuticals Inc. started a Phase IIIb study of the drug. (BioWorld Today)
RSS